Cargando…

Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review

BACKGROUND: At low doses, naltrexone (LDN) has been shown to modulate inflammation through the interruption of microglial cell activation within the central nervous system. One of the most likely contributors to centralized pain is changes in microglial cell processing. Therefore, it has been postul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rupp, Adam, Young, Erin, Chadwick, Andrea L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Special Populations Section
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628981/ https://www.ncbi.nlm.nih.gov/pubmed/37302106 http://dx.doi.org/10.1093/pm/pnad074

Ejemplares similares

ICD-11 Classification of Pediatric Chronic Pain Referrals in Ireland, with Secondary Analysis of Primary vs Secondary Pain Conditions
por: Matthews, Eveline, et al.
Publicado: (2021)

Experiences of Patient-Led Chronic Pain Peer Support Groups After Pain Management Programs: A Qualitative Study
por: Farr, Michelle, et al.
Publicado: (2021)

Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome
por: Goebel, Andreas, et al.
Publicado: (2021)

Understanding the Pain Management Landscape Within the US Bleeding Disorder Community: A Multi-Center Survey
por: Witkop, Michelle, et al.
Publicado: (2021)

Randomized controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in adults with complex regional pain syndrome
por: Ratcliffe, Stuart, et al.
Publicado: (2022)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Prevalence and Impact of Dysmenorrhea Among University Students in Ireland
por: Durand, Hannah, et al.
Publicado: (2021)

The Effect of the Model’s Social Status on Placebo Analgesia Induced by Social Observational Learning
por: Bieniek, Helena, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Access to Medicaid and Medicare by the low-income disabled
por: Ellwood, Marilyn Rymer, et al.
Publicado: (1990)

Role of the central autonomic nervous system intrinsic functional organisation and psychosocial factors in primary microvascular angina and Takotsubo syndrome
por: Cattaneo, Magdalena Maria, et al.
Publicado: (2020)

Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
por: Toljan, Karlo, et al.
Publicado: (2018)

Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX‐02 in Patients With Nephropathic Cystinosis
por: Haverty, Thomas, et al.
Publicado: (2021)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease
por: Rothnie, Kieran J, et al.
Publicado: (2015)

Predicting mortality after acute coronary syndromes in people with chronic obstructive pulmonary disease
por: Rothnie, Kieran J, et al.
Publicado: (2016)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

The perceptions of general practice among Central and Eastern Europeans in the United Kingdom: A systematic scoping review
por: Poppleton, Aaron, et al.
Publicado: (2022)

Ventricular–vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension
por: Dufva, Melanie J, et al.
Publicado: (2021)

Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
por: Gille, Andreas, et al.
Publicado: (2018)

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
por: Hippisley-Cox, Julia, et al.
Publicado: (2020)

Cardiovascular disease in HIV patients: from bench to bedside and backwards
por: Cerrato, Enrico, et al.
Publicado: (2015)

Low-Dose Naltrexone in Rheumatological Diseases
por: de Carvalho, Jozélio Freire, et al.
Publicado: (2023)

Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction
por: Andell, Pontus, et al.
Publicado: (2014)

Medicaid-financed residential care for persons with mental retardation
por: Lakin, K. Charlie, et al.
Publicado: (1990)

Medicaid mysteries: Transitional benefits, Medicaid coverage, and welfare exits
por: Ellwood, David T., et al.
Publicado: (1990)

Cardiac troponin I but not cardiac troponin T adheres to polysulfone dialyser membranes in an in vitro haemodialysis model: explanation for lower serum cTnI concentrations following dialysis
por: Gaze, David C, et al.
Publicado: (2014)

Heart rate variability analysis during head-up tilt test predicts nitroglycerine-induced syncope
por: Efremov, Kristian, et al.
Publicado: (2014)

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment
por: Torres, Rosarelis, et al.
Publicado: (2015)

Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study
por: Arnott, Clare, et al.
Publicado: (2015)

Subclinical cardiopulmonary dysfunction in stage 3 chronic kidney disease
por: Nelson, Alexander, et al.
Publicado: (2016)

Maternal ethnicity and its impact on the haemodynamic and blood pressure response to labetalol for the treatment of antenatal hypertension
por: Stott, D, et al.
Publicado: (2016)

Effects of paediatric HIV infection on electrical conduction of the heart
por: Idris, Nikmah S, et al.
Publicado: (2016)

Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy
por: Hodes, Anke R, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fd7psi1orh7c686440ua062fbi